Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Complex analysis of the p53 tumor suppressor in lung carcinoma

J. Smardova, K. Liskova, B. Ravcukova, J. Malcikova, J. Hausnerova, M. Svitakova, R. Hrabalkova, L. Zlamalikova, K. Stano-Kozubik, I. Blahakova, J. Speldova, J. Jarkovsky, J. Smarda,

. 2016 ; 35 (3) : 1859-1867. [pub] 20151229

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000710

Grantová podpora
NT13784 MZ0 CEP - Centrální evidence projektů

Lung cancer is the leading cause of cancer-related deaths worldwide. The p53 tumor suppressor is a transcription factor controlling expression of its target genes in response to various stress stimuli. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000710
003      
CZ-PrNML
005      
20191022083341.0
007      
ta
008      
170103s2016 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/or.2015.4533 $2 doi
024    7_
$a 10.3892/or.2015.4533 $2 doi
035    __
$a (PubMed)26718964
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Šmardová, Jana, $u Department of Pathology, University Hospital, Brno, Czech Republic. $d 1961- $7 mzk2005304278
245    10
$a Complex analysis of the p53 tumor suppressor in lung carcinoma / $c J. Smardova, K. Liskova, B. Ravcukova, J. Malcikova, J. Hausnerova, M. Svitakova, R. Hrabalkova, L. Zlamalikova, K. Stano-Kozubik, I. Blahakova, J. Speldova, J. Jarkovsky, J. Smarda,
520    9_
$a Lung cancer is the leading cause of cancer-related deaths worldwide. The p53 tumor suppressor is a transcription factor controlling expression of its target genes in response to various stress stimuli. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.
650    _2
$a adenokarcinom $x genetika $x patologie $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nemalobuněčný karcinom plic $x genetika $x patologie $7 D002289
650    _2
$a spinocelulární karcinom $x genetika $x patologie $7 D002294
650    _2
$a nádorová transformace buněk $x genetika $7 D002471
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a nádory plic $x genetika $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a nádorový supresorový protein p53 $x genetika $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Matulová, Květoslava $u Department of Pathology, University Hospital, Brno, Czech Republic. $7 mub20221162733
700    1_
$a Ravčuková, Barbora $u Molecular Genetics Laboratory, Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic. $7 xx0105242
700    1_
$a Malčíková, Jitka, $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. $d 1979- $7 mub2011655946
700    1_
$a Hausnerová, Jitka $u Department of Pathology, University Hospital, Brno, Czech Republic. $7 xx0228420
700    1_
$a Svitáková, Miluše $u Department of Pathology, University Hospital, Brno, Czech Republic. $7 xx0128956
700    1_
$a Hrabálková, Renata $u Department of Pathology, University Hospital, Brno, Czech Republic. $7 xx0127436
700    1_
$a Zlamalikova, Lenka $u Department of Pathology, University Hospital, Brno, Czech Republic.
700    1_
$a Staňo Kozubík, Kateřina $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. $7 xx0141563
700    1_
$a Blaháková, Ivona $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. $7 xx0119176
700    1_
$a Špeldová, Jana $u Department of Respiratory Diseases and TB, University Hospital, Brno, Czech Republic. $7 xx0227816
700    1_
$a Jarkovský, Jiří, $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. $d 1976- $7 stk2008461294
700    1_
$a Šmarda, Jan, $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. $d 1961- $7 mzk2006343362
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 35, č. 3 (2016), s. 1859-1867
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26718964 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20191022083815 $b ABA008
999    __
$a ok $b bmc $g 1179850 $s 961277
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 35 $c 3 $d 1859-1867 $e 20151229 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
GRA    __
$a NT13784 $p MZ0
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace